Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
By Masatoshi Kudo, Richard S. Finn, S. Qin, K. Han, Kenji Ikeda, F. Piscaglia, A. Baron, Joong-Won Park, G. Han, J. Jassem and 12 more. The Lancet, 2018
4,560 citations recorded by the source corpus.
BACKGROUND In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. METHODS This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Patients were randomly assigned (1:1) via an interactive voice-web response system-with region; macroscopic portal vein invasion, extrahepatic spread, or both; Eastern Cooperative Oncology Group performance status; and bodyweight as stratification factors-to receive oral lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg) or sorafenib 400 mg twice-daily in 28-day cycles. The primary endpoint was overall survival, measured from the date of randomisation until the date of death from any cause. The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. The non-inferiority margin was set at 1·08. The trial is registered with ClinicalTrials.gov, number NCT01761266. FINDINGS Between March 1, 2013 and July 30, 2015, 1492 patients were recruited. 954 eligible patients were randomly assigned to lenvatinib (n=478) or sorafenib (n=476). Median survival time for lenvatinib of 13·6 months (95% CI 12·1-14·9) was non-inferior to sorafenib (12·3 months, 10·4-13·9; hazard ratio 0·92, 95% CI 0·79-1·06), meeting criteria for non-inferiority. The most common any-grade adverse events were hypertension (201 [42%]), diarrhoea (184 [39%]), decreased appetite (162 [34%]), and decreased weight (147 [31%]) for lenvatinib, and palmar-plantar erythrodysaesthesia (249 [52%]), diarrhoea (220 [46%]), hypertension (144 [30%]), and decreased appetite (127 [27%]) for sorafenib. INTERPRETATION Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability profiles of lenvatinib were consistent with those previously observed. FUNDING Eisai Inc.
Subfields: Hepatology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/915e4468c664dec61e2fe42bc6b6762bc199fd15
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- Amit G. Singal
- Andrew X. Zhu
- L. Kulik
- R. Finn
- Lewis R. Roberts
- J. Llovet
- Claude B. Sirlin
- J. Heimbach
In Molecular Biology
Citations in the corpus
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018, background): “Recently, data from an open-label, randomized phase 3 trial of the multikinase inhibitor, lenvatinib, versus sorafenib was reported(168) (Table 3).”
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, background): “Indeed, typically ~20% of patients included in phase III trials to test systemic therapies have intermediate-stage HCC unamenable or unresponsive to locoregional therapies 177–179 .”
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. (2019, background): “All of these are antiangiogenic agents, including tyrosine kinase inhibitors lenvatinib in the first-line setting and regorafenib, cabozantinib, and the monoclonal antibody ramucirumab in the second-line setting after prior sorafenib therapy.(3-6)”
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “IMbrave150 [312] HIMALAYA [323] REFLECT [313] Study TABLE 8 Summary efficacy data for selected second line studies after prior sorafenib therapy Aspect CELESTIAL [314] RESORCE [315] REACH-2 [127] KEYNOTE-240 [316] KEYNOTE-394 [317] CheckMate 040 [318] Study”
- Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma (2018, neutral): “Lenvatinib, a multi-kinase inhibitor, could be admitted as the first line treatment of unresectable advanced HCC in a randomized phase III non-inferiority trial [7].”
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “1 μM), RET, and FGFRs, inhibits angiogenesis induced by Ret mutation and lymphogenesis mediated by VEGFR-3 (Table 1).(434,435) In 2016, the combination of lenvatinib with mTOR inhibitor everolimus (Table 1) was approved for advanced RCC (NCT01136733).”
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020, neutral): “AST increased 20 (20) 4 (4) 5 (5) 11 (11) Proteinuria 20 (20) 9 (9) 7 (7) 4 (4) Asthenia 19 (19) 4 (4) 10 (10) 5 (5)”